Patents by Inventor Pablo Martin Pascual
Pablo Martin Pascual has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9422228Abstract: 3,3-diphenylpropylamines of general formula (I), particularly Fesoterodine, as well as their enantiomers, solvates and salts, can be produced by treating a compound of formula (II) with a chiral alcohol to yield the diastereomeric esters of formula (IV) and (IV?), which can be further transformed into a compound of formula (I), or an enantiomer, solvate or salt thereof, wherein R1 is C1-C8 alkyl; and R2 and R3, independently of one another, represent H or C1-C6 alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound.Type: GrantFiled: April 26, 2013Date of Patent: August 23, 2016Assignee: CRYSTAL PHARMA, S.A.U.Inventors: Antonio Lorente Bonde-Larsen, Francisco Javier Gallo Nieto, Juan José Ferreiro Gil, Pablo Martín Pascual
-
Publication number: 20150094485Abstract: 3,3-diphenylpropylamines of general formula (I), particularly Fesoterodine, as well as their enantiomers, solvates and salts, can be produced by treating a compound of formula (II) with a chiral alcohol to yield the diastereomeric esters of formula (IV) and (IV?), which can be further transformed into a compound of formula (I), or an enantiomer, solvate or salt thereof, wherein R1 is C1-C8 alkyl; and R2 and R3, independently of one another, represent H or C1-C6 alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound.Type: ApplicationFiled: April 26, 2013Publication date: April 2, 2015Inventors: Antonio Lorente Bonde-Larsen, Francisco Javier Gallo Nieto, Juan José Ferreiro Gil, Pablo Martín Pascual
-
Patent number: 8722920Abstract: The invention relates to a process for obtaining 3,3-diphenylpropylamines of general formula (I), particularly Fesoterodine, as well as their enantiomers, solvates and salts, comprising a chemoselective reduction of the acid group against the ester group in compounds of general formula (V), wherein R1 is C1-C8 alkyl; and R3 and R4, independently of one another, represent H or C1-C8 alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound. The invention also relates to the compounds of formula (V), as well as their enantiomers, solvates and salts.Type: GrantFiled: July 26, 2010Date of Patent: May 13, 2014Assignee: Crystal Pharma S.A.U.Inventors: Antonio Lorente Bonde-Larsen, Pablo Martín Pascual, Mario Laderas Muñoz, Luis Gerardo Gutiérrez Fuentes
-
Publication number: 20120220797Abstract: The invention relates to a process for obtaining 3,3-diphenylpropylamines of general formula (I), particularly Fesoterodine, as well as their enantiomers, solvates and salts, comprising a chemoselective reduction of the acid group against the ester group in compounds of general formula (V), wherein R1 is C1-C8 alkyl; and R3 and R4, independently of one another, represent H or C1-C8 alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound. The invention also relates to the compounds of formula (V), as well as their enantiomers, solvates and salts.Type: ApplicationFiled: July 26, 2010Publication date: August 30, 2012Inventors: Antonio Lorente Bonde-Larsen, Pablo Martín Pascual, Mario Laderas Muñoz, Luis Gerardo Gutiérrez Fuentes
-
Publication number: 20110319666Abstract: The invention relates to a method of obtaining 3,3-diphenylpropylamines (I), wherein R1 is H, alkyl, haloalkyl or alkoxyalkyl, R2 is alkyl, alkoxy, halogen, NO2, CN, CHO, which may be free or protected, CH2OH or COOR6, and R2 and R1 are selected independently from H and alkyl or together with the nitrogen to which they are bound form a ring having 3 to 7 members. The inventive method consists in reacting a propylenephenylamine and a disubstituted aromatic hydrocarbon and, if necessary, separating the desired enantiomer or the mixture of enantiomers, and/or converting the compound (I) into a salt. Compounds (I) are muscarinic receptor antagonists which can be used in the treatment of urinary incontinence and other symptoms of urinary bladder hyperactivity. Said compounds include tolterodine.Type: ApplicationFiled: September 7, 2011Publication date: December 29, 2011Inventors: Antonio Lorente Bonde-Larsen, Pablo Martin Pascual, Jorge Martin Juarez, Miquel Armengol Montserrat
-
Patent number: 8039672Abstract: The invention relates to a method of obtaining 3,3-diphenylpropylamines (I), wherein R1 is H, alkyl, haloalkyl or alkoxyalkyl, R2 is alkyl, alkoxy, halogen, NO2, CN, CHO, which may be free or protected, CH2OH or COOR6, and R3 and R4 are selected independently from H and alkyl or together with the nitrogen to which they are bound form a ring having 3 to 7 members. The inventive method consists in reacting a propylenephenylamine and a disubstituted aromatic hydrocarbon and, if necessary, separating the desired enantiomer or the mixture of enantiomers, and/or converting the compound (I) into a salt. Compounds (I) are muscarinic receptor antagonists which can be used in the treatment of urinary incontinence and other symptoms of urinary bladder hyperactivity. Said compounds include tolterodine.Type: GrantFiled: August 3, 2006Date of Patent: October 18, 2011Assignee: Interquim, S.A.Inventors: Antonio Lorente Bonde-Larsen, Pablo Martin Pascual, Jorge Martin Juarez, Miquel Armengol Montserrat
-
Publication number: 20100286446Abstract: The invention relates to a method of obtaining 3,3-diphenylpropylamines (I), wherein R1 is H, alkyl, haloalkyl or alkoxyalkyl, R2 is alkyl, alkoxy, halogen, NO2, CN, CHO, which may be free or protected, CH2OH or COOR6, and R3 and R4 are selected independently from H and alkyl or together with the nitrogen to which they are bound form a ring having 3 to 7 members. The inventive method consists in reacting a propylenephenylamine and a disubstituted aromatic hydrocarbon and, if necessary, separating the desired enantiomer or the mixture of enantiomers, and/or converting the compound (I) into a salt. Compounds (I) are muscarinic receptor antagonists which can be used in the treatment of urinary incontinence and other symptoms of urinary bladder hyperactivity. Said compounds include tolterodine.Type: ApplicationFiled: August 3, 2006Publication date: November 11, 2010Applicant: Interquim, S.A.Inventors: Antonio Lorente Bonde-Larsen, Pablo Martin Pascual, Jorge Martin Juarez, Miquel Armengol Montserrat
-
Patent number: 7473805Abstract: The process comprises reacting a compound of formula (II), where R is a hydroxyl protecting group, and the asterisk indicates an asymmetric carbon atom, with diisopropylamine in the presence of a reducing agent; optionally converting the resulting intermediate into a salt and, if so desired, isolating it; removing the hydroxyl protecting group; and if so desired, separating the desired (R) or (S) enantiomer, or the mixture of enantiomers and/or converting the obtained compound into a pharmaceutically acceptable salt thereof. Tolterodine is a muscarinic receptor antagonist useful in treating urinary incontinence and other symptoms of urinary bladder hyperactivity.Type: GrantFiled: December 21, 2004Date of Patent: January 6, 2009Assignee: Ragactives, S.L. Parque Tecnologico de BoecilloInventors: Gustavo Pascual Coca, Pablo Martin Pascual, Jorge Martin Juarez
-
Publication number: 20070254959Abstract: The process comprises reacting a compound of formula (II), where R is a hydroxyl protecting group, and the asterisk indicates an asymmetric carbon atom, with diisopropylamine in the presence of a reducing agent; optionally converting the resulting intermediate into a salt and, if so desired, isolating it; removing the hydroxyl protecting group; and if so desired, separating the desired (R) or (S) enantiomer, or the mixture of enantiomers and/or converting the obtained compound into a pharmaceutically acceptable salt thereof. Tolterodine is a muscarinic receptor antagonist useful in treating urinary incontinence and other symptoms of urinary bladder hyperactivity.Type: ApplicationFiled: December 21, 2004Publication date: November 1, 2007Applicant: RAGACTIVES, S.L.Inventors: Gustavo Pascual Coca, Pablo Martin Pascual, Jorge Martin Juarez